TY - JOUR
T1 - Genetic Landscape of the ACE2 Coronavirus Receptor
AU - GenOMICC Consortium and the IMI-DIRECT Consortium
AU - Yang, Zhijian
AU - MacDonald-Dunlop, Erin
AU - Chen, Jiantao
AU - Zhai, Ranran
AU - Li, Ting
AU - Richmond, Anne
AU - Klaric, Lucija
AU - Pirastu, Nicola
AU - Ning, Zheng
AU - Zheng, Chenqing
AU - Wang, Yipeng
AU - Huang, Tingting
AU - He, Yazhou
AU - Guo, Huiming
AU - Ying, Kejun
AU - Gustafsson, Stefan
AU - Prins, Bram
AU - Ramisch, Anna
AU - Dermitzakis, Emmanouil T
AU - Png, Grace
AU - Eriksson, Niclas
AU - Haessler, Jeffrey
AU - Hu, Xiaowei
AU - Zanetti, Daniela
AU - Boutin, Thibaud
AU - Hwang, Shih-Jen
AU - Wheeler, Eleanor
AU - Pietzner, Maik
AU - Raffield, Laura M
AU - Kalnapenkis, Anette
AU - Peters, James E
AU - Viñuela, Ana
AU - Gilly, Arthur
AU - Elmståhl, Sölve
AU - Dedoussis, George
AU - Petrie, John R
AU - Polašek, Ozren
AU - Folkersen, Lasse
AU - Chen, Yan
AU - Yao, Chen
AU - Võsa, Urmo
AU - Pairo-Castineira, Erola
AU - Clohisey, Sara
AU - Bretherick, Andrew D
AU - Rawlik, Konrad
AU - Esko, Tõnu
AU - Enroth, Stefan
AU - Johansson, Åsa
AU - Gyllensten, Ulf
AU - Langenberg, Claudia
AU - Levy, Daniel
AU - Hayward, Caroline
AU - Assimes, Themistocles L
AU - Kooperberg, Charles
AU - Manichaikul, Ani W
AU - Siegbahn, Agneta
AU - Wallentin, Lars
AU - Lind, Lars
AU - Zeggini, Eleftheria
AU - Schwenk, Jochen M
AU - Butterworth, Adam S
AU - Michaëlsson, Karl
AU - Pawitan, Yudi
AU - Joshi, Peter K
AU - Baillie, J Kenneth
AU - Mälarstig, Anders
AU - Reiner, Alexander P
AU - Wilson, James F
AU - Shen, Xia
N1 - Funding Information:
Dr Shen received a Swedish Research Council Starting Grant (No. 2017-02543) and National Natural Science Foundation of China grant (No. 12171495). Drs Wilson and Hayward acknowledge support from the Medical Research Council Human Genetics Unit program grant “Quantitative Traits in Health and Disease” (U. MC_UU_00007/10). The work of Dr Klaric was supported by an RCUK Innovation Fellowship from the National Productivity Investment Fund (MR/R026408/1). Drs Zanetti, Petrie, and Assimes were supported by grant R01DK114183. Dr Bretherick acknowledges funding from the Wellcome PhD training fellowship for clinicians (204979/Z/16/Z), the Edinburgh Clinical Academic Track program. Dr Reiner was supported by grants R01HL146500 and R01HL132947.
Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/5/3
Y1 - 2022/5/3
N2 - BACKGROUND: SARS-CoV-2, the causal agent of COVID-19, enters human cells using the ACE2 (angiotensin-converting enzyme 2) protein as a receptor. ACE2 is thus key to the infection and treatment of the coronavirus. ACE2 is highly expressed in the heart and respiratory and gastrointestinal tracts, playing important regulatory roles in the cardiovascular and other biological systems. However, the genetic basis of the ACE2 protein levels is not well understood.METHODS: We have conducted the largest genome-wide association meta-analysis of plasma ACE2 levels in >28 000 individuals of the SCALLOP Consortium (Systematic and Combined Analysis of Olink Proteins). We summarize the cross-sectional epidemiological correlates of circulating ACE2. Using the summary statistics-based high-definition likelihood method, we estimate relevant genetic correlations with cardiometabolic phenotypes, COVID-19, and other human complex traits and diseases. We perform causal inference of soluble ACE2 on vascular disease outcomes and COVID-19 severity using mendelian randomization. We also perform in silico functional analysis by integrating with other types of omics data.RESULTS: We identified 10 loci, including 8 novel, capturing 30% of the heritability of the protein. We detected that plasma ACE2 was genetically correlated with vascular diseases, severe COVID-19, and a wide range of human complex diseases and medications. An X-chromosome cis-protein quantitative trait loci-based mendelian randomization analysis suggested a causal effect of elevated ACE2 levels on COVID-19 severity (odds ratio, 1.63 [95% CI, 1.10-2.42];
P=0.01), hospitalization (odds ratio, 1.52 [95% CI, 1.05-2.21];
P=0.03), and infection (odds ratio, 1.60 [95% CI, 1.08-2.37];
P=0.02). Tissue- and cell type-specific transcriptomic and epigenomic analysis revealed that the ACE2 regulatory variants were enriched for DNA methylation sites in blood immune cells.
CONCLUSIONS: Human plasma ACE2 shares a genetic basis with cardiovascular disease, COVID-19, and other related diseases. The genetic architecture of the ACE2 protein is mapped, providing a useful resource for further biological and clinical studies on this coronavirus receptor.
AB - BACKGROUND: SARS-CoV-2, the causal agent of COVID-19, enters human cells using the ACE2 (angiotensin-converting enzyme 2) protein as a receptor. ACE2 is thus key to the infection and treatment of the coronavirus. ACE2 is highly expressed in the heart and respiratory and gastrointestinal tracts, playing important regulatory roles in the cardiovascular and other biological systems. However, the genetic basis of the ACE2 protein levels is not well understood.METHODS: We have conducted the largest genome-wide association meta-analysis of plasma ACE2 levels in >28 000 individuals of the SCALLOP Consortium (Systematic and Combined Analysis of Olink Proteins). We summarize the cross-sectional epidemiological correlates of circulating ACE2. Using the summary statistics-based high-definition likelihood method, we estimate relevant genetic correlations with cardiometabolic phenotypes, COVID-19, and other human complex traits and diseases. We perform causal inference of soluble ACE2 on vascular disease outcomes and COVID-19 severity using mendelian randomization. We also perform in silico functional analysis by integrating with other types of omics data.RESULTS: We identified 10 loci, including 8 novel, capturing 30% of the heritability of the protein. We detected that plasma ACE2 was genetically correlated with vascular diseases, severe COVID-19, and a wide range of human complex diseases and medications. An X-chromosome cis-protein quantitative trait loci-based mendelian randomization analysis suggested a causal effect of elevated ACE2 levels on COVID-19 severity (odds ratio, 1.63 [95% CI, 1.10-2.42];
P=0.01), hospitalization (odds ratio, 1.52 [95% CI, 1.05-2.21];
P=0.03), and infection (odds ratio, 1.60 [95% CI, 1.08-2.37];
P=0.02). Tissue- and cell type-specific transcriptomic and epigenomic analysis revealed that the ACE2 regulatory variants were enriched for DNA methylation sites in blood immune cells.
CONCLUSIONS: Human plasma ACE2 shares a genetic basis with cardiovascular disease, COVID-19, and other related diseases. The genetic architecture of the ACE2 protein is mapped, providing a useful resource for further biological and clinical studies on this coronavirus receptor.
KW - Angiotensin-Converting Enzyme 2/genetics
KW - COVID-19/genetics
KW - Cross-Sectional Studies
KW - Genome-Wide Association Study
KW - Humans
KW - Receptors, Coronavirus
KW - SARS-CoV-2
U2 - 10.1161/CIRCULATIONAHA.121.057888
DO - 10.1161/CIRCULATIONAHA.121.057888
M3 - Article
C2 - 35387486
SN - 0009-7322
VL - 145
SP - 1398
EP - 1411
JO - Circulation
JF - Circulation
IS - 18
ER -